Meningococcal vaccine GSK134612 (Nimenrix)

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, Meningococcal

Phase 2

Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects

CompletedNCT00661557

GlaxoSmithKlineInfections, Meningococcal

Start: 2008-05-19End: 2008-12-19Updated: 2018-12-28

Phase 3

Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children

CompletedNCT00474266

GlaxoSmithKlineInfections, Meningococcal

Start: 2007-06-05End: 2008-03-26Updated: 2019-11-18

Related Papers

Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.

2015-12-0120 citations

The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.

2012-06-1419 citations

Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial.

2011-04-0661 citations